Preclinical development of EXT608, an investigational parathyroid hormone derivative with extended half-life for the treatment of hypoparathyroidism is a research paper published in JBMR Plus (2024). On theSindex it has a DataRank of 0. It has been cited 5 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R44DK107231
National Institutes of Health
Grant: 2R44DK107231-04
Long-acting PTH for hypoparathyroidism
FWCI
2.12
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals